Proposed Rule to Modernize Drug Manufacturing Registration
FDA has issued a proposed a rule that would modernize drug establishment registration requirements by creating a streamlined pathway for distributed manufacturing facilities and clarifying registration obligations for certain foreign drug manufacturers, including active pharmaceutical ingredient (API) makers. The proposal is intended to reduce administrative burdens for companies using advanced manufacturing models while providing FDA with greater visibility into overseas drug supply chains that feed the U.S. market.
Under the proposed rule, distributed manufacturing operations that function as a single establishment through a centralized "hub-and-spoke" model would be allowed to register as one establishment rather than registering each manufacturing unit separately. According to FDA, distributed manufacturing facilities typically rely on a central quality oversight hub that manages multiple equivalent manufacturing units operating at different locations. Current regulations require each unit to register independently, an approach the agency said no longer reflects how these manufacturing networks operate.
If finalized, companies would be able to add, relocate, or remove manufacturing units through a streamlined update process. The proposal would also require firms to notify FDA before relocating a manufacturing unit, providing the agency with more timely oversight of manufacturing changes.
"The FDA is proposing changes to our establishment registration regulations that would reflect how distributed manufacturing actually works—as one single establishment," CDER acting director Michael Davis is quoted in a release as saying. He said the changes would make it easier for innovative manufacturers to operate efficiently while giving FDA "a clearer, more accurate picture of how and where drugs are being made."
The proposal also addresses what FDA described as a gap in oversight of certain foreign drug manufacturers. According to the agency, some foreign facilities that manufacture drugs or drug components, including APIs, exclusively for shipment to other foreign manufacturing establishments may not currently be registered with FDA, limiting the agency's visibility into upstream portions of the pharmaceutical supply chain before products ultimately enter the U.S. The proposed rule would clarify that these establishments are required to register with FDA and submit drug listing information, aligning the agency's regulations with statutory requirements.
"When an active ingredient in a medicine reaches an American patient, the FDA should be able to trace exactly where it came from," Davis said. "Closing this registration gap for foreign establishments is a concrete step toward increasing the supply chain transparency that patients deserve."